2nd Quarter - Report

THE SMITH-FREE GROUP, LLC for TEVA PHARMACEUTICALS USA, INC.

Firm
Client
Income
$80,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Discussions regarding the approval of generic drugs HR 2853 BLOCKING Act of 2021 (all sections of full text) Monitored PL 117-7 To prevent across-the-board direct spending cuts, and for other purposes Monitored Medicare and prescription drug changes

LobbyistCovered position, as disclosed
JACK S DEUSER —
JAMES C FREE —
MICHAEL A. GAFFIN New Leg. Director, Sen. Sherrod Brown; Leg. Director, Rep. Rob Andrews; Leg. Asst., Rep. Anna Eshoo; Jr. Leg. Assoc., House Ed and Labor Committee, Rep. George Miller; Staff Asst. Senate HELP Committee, Sen. Edward Kennedy
ROBERT HICKMOTT —
TREVOR W. KOLEGO —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2853 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.